TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35229631

Group type: EXPERIMENTAL
Intervention: Ureteral access sheath (UAS) 9.5F/11.5F (Group 1)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Ureteral access sheath (UAS) 12F/14F (Group 2)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Postoperative ureteral stricture
Number of subjects: 320
Study: 33581023

Group type: EXPERIMENTAL
Intervention: DePuy Synthes plate
Number of subjects: 100

Group type: COMPARATOR
Intervention: VariAx plate
Number of subjects: 100
Study: 36448255

Group type: EXPERIMENTAL
Intervention: Absorbable polysaccharide hemostatic agent
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (no hemostatic agent)
Number of subjects: 136
Study: 33359194

Group type: EXPERIMENTAL
Intervention: SBP ≤120 mm Hg
Number of subjects: 1481

Group type: EXPERIMENTAL
Intervention: Each 10 mm Hg decrement in SBP
Number of subjects: 1481

Group type: COMPARATOR
Intervention: SBP >120 mm Hg
Number of subjects: 1481
Study: 34166312

Group type: EXPERIMENTAL
Intervention: Targeted sample design based on maternal HIV status and mortality
Number of subjects: 8

Group type: COMPARATOR
Intervention: Geographically stratified 2-stage sample design
Number of subjects: 8
Study: 35045119

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 600

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 600
Study: 35544149

Group type: EXPERIMENTAL
Intervention: MucoRice-CTB 6 g
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MucoRice-CTB (any dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (any dose)
Number of subjects: 60
Study: 35920822

Group type: EXPERIMENTAL
Intervention: Blinded continuous glucose monitoring (CGM)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Unblinded continuous glucose monitoring (CGM) after 1 week
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Unblinded continuous glucose monitoring (CGM) after 2 weeks
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Unblinded continuous glucose monitoring (CGM) after 3 months
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Unblinded continuous glucose monitoring (CGM)
Number of subjects: 485
Study: 35171084

Group type: EXPERIMENTAL
Intervention: Interferential current (IFC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham IFC
Number of subjects: 60
Study: 34437410

Group type: EXPERIMENTAL
Intervention: Condensed RT (4 sessions/week for 6 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Distributed RT (2 sessions/week for 12 weeks)
Number of subjects: 36
Study: 32141273

Group type: EXPERIMENTAL
Intervention: Exercise and Sleep Optimization (ExS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Exercise only (Ex)
Number of subjects: 23
Study: 36130057

Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Survivorship Education (SE)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 247
Study: 33403743

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) assistance to mini-punch grafting (MPG)/phototherapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mini-punch grafting (MPG)/phototherapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: PRP-assisted method
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both treatments (MPG/phototherapy and PRP-assisted)
Number of subjects: 34
Study: 35731529

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 1000 mg on days 1 and 15, 500 mg maintenance at months 12 and 18
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patients with ARAs
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patients without ARAs
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Anti-desmoglein 3 antibodies (DSG3 Abs) levels
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: RTX concentration
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: B-cell depletion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Anti-desmoglein 3 Abs levels
Number of subjects: 42
Study: 33054842

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 34039025

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr) with the MitraClip
Number of subjects: 614

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 614
Study: 32024533

Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of 177Lu-DOTATATE
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intravenous administration of 177Lu-DOTATATE
Number of subjects: 26
Study: 32091613

Group type: EXPERIMENTAL
Intervention: Pre‐emptive intrathecal morphine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Post‐operative intrathecal morphine
Number of subjects: 90

Group type: COMPARATOR
Intervention: General anesthesia (Group I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Post‐operative intrathecal morphine (Group III)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pre‐emptive intrathecal morphine (Group II)
Number of subjects: 90
Study: 33669174

Group type: EXPERIMENTAL
Intervention: PediaFit 1.1 (n = 24)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: PediaFit 1.2 (n = 30)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (n = 49)
Number of subjects: 103
Study: 34559185

Group type: EXPERIMENTAL
Intervention: Breath‐O Correct lenses worn overnight for 3 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 32131801

Group type: EXPERIMENTAL
Intervention: Conventional management of carious lesions and prevention (C + P)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Biological management of carious lesions and prevention (B + P)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prevention alone (PA)
Number of subjects: 31
Study: 35290464

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 15081

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15081

Group type: EXPERIMENTAL
Intervention: Empagliflozin (sensitivity analysis)
Number of subjects: 15081
Study: 33962762

Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (2400 mg) administered concomitantly with roxadustat (200 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Calcium acetate (1900 mg) administered concomitantly with roxadustat (200 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg) administered 1 hour before sevelamer carbonate
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg) administered 1 hour after sevelamer carbonate
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg) administered 1 hour before calcium acetate
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg) administered 1 hour after calcium acetate
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg) administered 2 to 3 hours after sevelamer carbonate
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg) administered 2 to 3 hours after calcium acetate
Number of subjects: 84
Study: 35654369

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Constant-load exercise (CLE)
Number of subjects: 55
Study: 34641865

Group type: EXPERIMENTAL
Intervention: Home visits to pregnant women and their spouses every 2 months during pregnancy, with a follow-up visit 12-18 months after birth.
Number of subjects: 6905
Study: 32417502

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Office-based kyphoplasties
Number of subjects: 0
Study: 35748625

Group type: EXPERIMENTAL
Intervention: modified Attachment Behavioral Catch‐up (mABC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: modified Developmental Education for Families (mDEF)
Number of subjects: 36
Study: 32100576

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (15 minutes, twice a week)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (RT alone without acupuncture)
Number of subjects: 25
Study: 36305696

Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study: 34281145

Group type: EXPERIMENTAL
Intervention: Bullying involvement (perpetrators, victims, bully-victims)
Number of subjects: 4469

Group type: EXPERIMENTAL
Intervention: Individual factors
Number of subjects: 4469

Group type: EXPERIMENTAL
Intervention: Peer factors
Number of subjects: 4469

Group type: EXPERIMENTAL
Intervention: School factors
Number of subjects: 4469
Study: 33239012

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) viral load testing
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Task-shifting to enrolled nurses
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: POC VL testing and task-shifting combined
Number of subjects: 55
Study: 33504897

Group type: EXPERIMENTAL
Intervention: Genetically predicted increased gene expression of 12 genes associated with glioma risk.
Number of subjects: 7400

Group type: EXPERIMENTAL
Intervention: Tissue-specific eQTLs from brain tissues.
Number of subjects: 7400

Group type: EXPERIMENTAL
Intervention: MR and colocalisation approach.
Number of subjects: 7400

Group type: EXPERIMENTAL
Intervention: Correlation of MR estimates in brain and blood.
Number of subjects: 7400
Study: 32833564

Group type: EXPERIMENTAL
Intervention: Inotersen (TEGSEDI™)
Number of subjects: 0
Study: 35962349

Group type: EXPERIMENTAL
Intervention: Zishen Pingchan granules (ZPG)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 34434911

Group type: EXPERIMENTAL
Intervention: School-based intervention to promote cycling to school, involving 27 behavior change techniques over a 12-week practical phase and an 8-week preparatory phase.
Number of subjects: 250
Study: 32112140

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Focal and peripheral laser treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 31

Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 31
Study: 33580636

Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol, 50,000 IU/dose)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 35235142

Group type: EXPERIMENTAL
Intervention: SMS text‐delivered scheduled gradual smoking reduction (SGR) program plus support texts
Number of subjects: 314

Group type: COMPARATOR
Intervention: Support messages only
Number of subjects: 314
Study: 34520679

Group type: EXPERIMENTAL
Intervention: Intervention in overdose events by peer responders
Number of subjects: 61

Group type: COMPARATOR
Intervention: Previous intervention efforts
Number of subjects: 61
Study: 32069236

Group type: EXPERIMENTAL
Intervention: LCPUFA-ω3 (DO3)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (DP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cross-sectional analysis
Number of subjects: 180
Study: 35647977

Group type: EXPERIMENTAL
Intervention: Green light (n = 55)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Yellow light (n = 45)
Number of subjects: 100
Study: 32677987

Group type: EXPERIMENTAL
Intervention: Collaborating Across Systems for Program Implementation (CASPI) tool
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CASPI tool
Number of subjects: 17
Study: 34791499

Group type: EXPERIMENTAL
Intervention: MA health coaching intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 33663862

Group type: EXPERIMENTAL
Intervention: LP4
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: LP8
Number of subjects: 51

Group type: COMPARATOR
Intervention: LP0
Number of subjects: 51
Study: 32409982

Group type: COMPARATOR
Intervention: 5 mg/kg CBD
Number of subjects: 24

Group type: COMPARATOR
Intervention: 10 mg/kg CBD
Number of subjects: 24

Group type: COMPARATOR
Intervention: 20 mg/kg CBD
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CBD (all doses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 34859604

Group type: EXPERIMENTAL
Intervention: High social status position (experimental manipulation)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Low social status position (experimental manipulation)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Identifying as low subjective social status (SSS)
Number of subjects: 133
Study: 34130026

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MedDiet)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non MedDiet plus nuts (50 g/day)
Number of subjects: 44
Study: 33906126

Group type: EXPERIMENTAL
Intervention: Aerosolized hyaluronan (HA) - 3 ml inhalation solution containing 0.03% HA, self-administered twice daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aerosolized hyaluronan (HA)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 33412023

Group type: EXPERIMENTAL
Intervention: Tunable cross‐Kerr‐type ZZ interaction with a flux‐tunable coupler element, performing a conditional phase CZ gate.
Number of subjects: 0
Study: 33482134

Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4 mg
Number of subjects: 116
Study: 32434470

Group type: EXPERIMENTAL
Intervention: GlideScope®
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: C-MAC®(D)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 90
Study: 36093393

Group type: EXPERIMENTAL
Intervention: Medical‐nursing integrated nursing group (study group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General nursing group (control group)
Number of subjects: 0
Study: 33271178

Group type: EXPERIMENTAL
Intervention: 4 mg/mL dexamethasone
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 25 mg/mL diclofenac sodium
Number of subjects: 117

Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 117
Study: 35286282

Group type: EXPERIMENTAL
Intervention: CEAA supplementation (oral, twice daily for 2 weeks)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard nutrition (control group)
Number of subjects: 400
Study: 35773443

Group type: EXPERIMENTAL
Intervention: Tailored intensive lifestyle modification program
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320
Study: 33103727

Group type: EXPERIMENTAL
Intervention: Regression-based prediction models for cognitive and emotional test scores in early-stage idiopathic PD
Number of subjects: 688

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 688
Study: 32847919

Group type: EXPERIMENTAL
Intervention: Protocols published after the SPIRIT statement (2013)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Protocols published before the SPIRIT statement (2013)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall improvement since the SPIRIT statement
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Individual checklist items reporting
Number of subjects: 300
Study: 35383071

Group type: EXPERIMENTAL
Intervention: IV ketorolac 0.5 mg/kg + IV morphine placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: IV morphine 0.1 mg/kg + IV ketorolac placebo
Number of subjects: 100
Study: 34106990

Group type: EXPERIMENTAL
Intervention: C-reactive protein guided antibiotherapy with levofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-day antibiotherapy with levofloxacin
Number of subjects: 0
Study: 32170789

Group type: EXPERIMENTAL
Intervention: 20 mg/kg lycopene
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: 40 mg/kg lycopene
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: 80 mg/kg lycopene
Number of subjects: 720

Group type: COMPARATOR
Intervention: 0 mg/kg lycopene (control group)
Number of subjects: 720
Study: 35061634

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ISBPB with ICPB (BC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ultrasound-guided CPB with ICPB (CC)
Number of subjects: 40
Study: 33451925

Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy (RA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Modified Balloon (MB)
Number of subjects: 200
Study: 32474612

Group type: EXPERIMENTAL
Intervention: Conservative treatment for zone 1 fractures
Number of subjects: 1239

Group type: COMPARATOR
Intervention: Surgical treatment for zone 1 fractures
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Conservative treatment for Jones' (zone 2) fractures
Number of subjects: 1239

Group type: COMPARATOR
Intervention: Surgical treatment for Jones' (zone 2) fractures
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Proximal diaphyseal (zone 3) fractures
Number of subjects: 1239
Study: 32618838

Group type: EXPERIMENTAL
Intervention: Noninvasive vagus nerve stimulation (nVNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 0
Study: 33464986

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment model for high school students with ASD
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Parent and teacher reports of school support intensity
Number of subjects: 544
Study: 34528462

Group type: EXPERIMENTAL
Intervention: Diverse juries (ambiguous evidence)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Diverse juries (wealth and power conditions)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Nondiverse juries (ambiguous evidence)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Nondiverse juries (wealth and power conditions)
Number of subjects: 802
Study: 32023526

Group type: EXPERIMENTAL
Intervention: Smartphone mobile app
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 181
Study: 34171159

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 176
Study: 34483022

Group type: EXPERIMENTAL
Intervention: 100 µg QS-21-containing C difficile vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 or 200 µg unadjuvanted C difficile vaccine formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35169011

Group type: EXPERIMENTAL
Intervention: Migraine preventive medication without switching of the overused medication
Number of subjects: 720

Group type: COMPARATOR
Intervention: Migraine preventive medication with switching from the overused medication
Number of subjects: 720
Study: 32146521

Group type: EXPERIMENTAL
Intervention: Uterosacral ligament suspension (ULS)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation (SSLF)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Advanced prolapse
Number of subjects: 374
Study: 35813030

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33414442

Group type: EXPERIMENTAL
Intervention: BNC210 (300 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BNC210 (2000 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BNC210 (200 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lorazepam (1.5 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BNC210 (low dose)
Number of subjects: 21
Study: 32129101

Group type: EXPERIMENTAL
Intervention: GIK infusion with supportive care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 60
Study: 34991510

Group type: EXPERIMENTAL
Intervention: AJoM program (classroom-based physical activity breaks) implemented for eight weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AJoM program (classroom-based physical activity breaks)
Number of subjects: 40
Study: 33616643

Group type: EXPERIMENTAL
Intervention: Avexitide 30 mg twice daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Avexitide 60 mg once daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 32421841

Group type: EXPERIMENTAL
Intervention: 5 mg intramuscular naloxone hydrochloride (PFS)
Number of subjects: 14
Study: 35086184

Group type: EXPERIMENTAL
Intervention: Podcasts and online CR modules
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pre-established online CR modules
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Podcasts
Number of subjects: 48
Study: 35340943

Group type: EXPERIMENTAL
Intervention: Glidescope videolaryngoscope (Group GVL, N = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (Group L, N = 60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 36044209

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 25119

Group type: EXPERIMENTAL
Intervention: Female sex with adjustment for race and ethnicity, smoking, alcohol intake, hypertension, diabetes, thyroid disease, exercise, and BMI
Number of subjects: 25119

Group type: EXPERIMENTAL
Intervention: Female sex with height
Number of subjects: 25119

Group type: EXPERIMENTAL
Intervention: Female sex with height and weight
Number of subjects: 25119

Group type: EXPERIMENTAL
Intervention: Female sex with body surface area (BSA)
Number of subjects: 25119
Study: 34636520

Group type: EXPERIMENTAL
Intervention: 20U incobotulinumtoxinA (INCO)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: 50U incobotulinumtoxinA (INCO)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: 75U incobotulinumtoxinA (INCO)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: 100U incobotulinumtoxinA (INCO)
Number of subjects: 241
Study: 36113856

Group type: EXPERIMENTAL
Intervention: DrySee dressing (DSD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tegaderm + Pad (comparator)
Number of subjects: 20
Study: 33104176

Group type: EXPERIMENTAL
Intervention: Plasmalike isotonic fluid therapy (140 mmol/L sodium and 5 mmol/L potassium in 5% dextrose)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Moderately hypotonic fluid therapy (80 mmol/L sodium and 20 mmol/L potassium in 5% dextrose)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Plasmalike isotonic fluid therapy
Number of subjects: 614

Group type: COMPARATOR
Intervention: Moderately hypotonic fluid therapy
Number of subjects: 614
Study: 33090505

Group type: EXPERIMENTAL
Intervention: lottery incentive group
Number of subjects: 244

Group type: COMPARATOR
Intervention: waitlist (delayed incentive) control group
Number of subjects: 244